BOLT vs EXPD · rev $7.7M vs P/E 26, rev $10.60B
Bolt Biotherapeutics (BOLT) versus Expeditors International of Washington, Inc. (EXPD) — a side-by-side from cached financials, not a winner call.
Bolt Biotherapeutics (BOLT) is a biotechnology company listed on US.
Expeditors International of Washington, Inc. (EXPD) is a integrated freight & logistics company listed on NYSE.
Latest reported BOLT revenue for 2024-12-31 was $7.7M. Net income was -$63.1M. Revenue was down 2.4% from 2023-12-31 to 2024-12-31. BOLT currently screens at market cap $11.3M.
Latest reported EXPD revenue for 2024-12-31 was $10.60B. Net income was $811.6M. Revenue was up 14.0% from 2023-12-31 to 2024-12-31. EXPD currently screens at market cap $21.01B and trailing P/E 26.0.
BOLT currently screens at market cap $11.3M. EXPD currently screens at market cap $21.01B and trailing P/E 26.0.
Not investment advice. Open the BOLT and EXPD stock pages for the full models.
Not investment advice.